Search

Revvity Inc

Geschlossen

BrancheGesundheitswesen

112.83 -0.72

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

112.19

Max

113.53

Schlüsselkennzahlen

By Trading Economics

Einkommen

-58M

41M

Verkäufe

-61M

711M

KGV

Branchendurchschnitt

51.957

64.641

EPS

1.06

Dividendenrendite

0.25

Gewinnspanne

5.726

Angestellte

11,000

EBITDA

-38M

180M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

-2.02% downside

Dividenden

By Acuity

Dividendenrendite

Branchendurchschnitt

0.25%

2.31%

Nächstes Ergebnis

4. Aug. 2026

Nächste Dividendenausschüttung

7. Aug. 2026

Nächstes Ex-Dividendendatum

16. Okt. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

2.4B

12B

Vorheriger Eröffnungskurs

113.55

Vorheriger Schlusskurs

112.83

Nachrichtenstimmung

By Acuity

20%

80%

36 / 340 Ranking in Healthcare

Revvity Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

31. Juli 2026, 19:16 UTC

Revvity Inc shares are lower today amid broader market declines, influenced by rising yields and inflation concerns following a significant increase in crude oil prices.

29. Juli 2026, 20:08 UTC

Revvity Inc shares are higher today, reflecting a steady upward trend amid rising oil prices and broader market influences. The stock is near its one-month range high.

28. Juli 2026, 20:03 UTC

Revvity Inc shares are higher during Tuesday's session, continuing their advance since Monday's close, despite broader market weakness in Asian indices.

27. Juli 2026, 21:02 UTC

Revvity Inc shares are lower in after-market hours, continuing a downward trend with three consecutive daily declines. No specific news was identified for the movement.

22. Juli 2026, 18:51 UTC

Revvity Inc shares are higher since Tuesday's close amid broader market gains, influenced by rising crude oil prices from geopolitical tensions involving the U.S. and Iran.

21. Juli 2026, 20:02 UTC

Revvity Inc shares are higher, supported by renewed interest in AI stocks and anticipation of earnings from major companies like Alphabet and Tesla.

20. Juli 2026, 19:21 UTC

News

Revvity Inc. published its 2026 Impact Report, disclosing Scope 3 emissions. Shares are lower amid broader industry challenges and a cautious analyst outlook.

Peer-Vergleich

Kursveränderung

Revvity Inc Prognose

Kursziel

By TipRanks

-2.02% Nachteil

12-Monats-Prognose

Durchschnitt 110.25 USD  -2.02%

Hoch 130 USD

Tief 90 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Revvity Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

12 ratings

4

Buy

8

Halten

0

Sell

Stimmung

By Acuity

36 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Revvity Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat